Comprehensive evidence for the pathogenicity of the <i>BRCA2</i> c.7847C&gt;T (p.Ser2616Phe) variant specific to the Japanese population

By integrating newly collected genetic data with functional and clinical evidence, we provide robust support for reclassifying the <i>BRCA2</i> c.7847C>T (p.Ser2616Phe) variant as 'Pathogenic'. This reclassification is crucial for ensuring that eligible Japanese patients gain access to appropriate targeted therapies.